<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087242</url>
  </required_header>
  <id_info>
    <org_study_id>2008L00307</org_study_id>
    <nct_id>NCT01087242</nct_id>
  </id_info>
  <brief_title>Clinical Trail of Tang-min-Ling Pills in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Randomized，Double-blind，Dose Parallel Controlled, Multicentre Clinical Trail of Tang-min-Ling Pills and Placebo in Diabetes Mellitus(Liver-stomach Heat Retention Syndrome) (Phase Ⅲ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Tasly Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, doubled blind, dose-paralleled control, multi-centre clinical trail,to
      evaluate the efficacy of Tang-min-ling pills in the treatment of type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus combined liver-stomach heat retension syndrome were recruited, which
      were divided into 3 groups .The patients were randomly taken with high-dosage (12g
      Tang-min-ling pills every time), low-dosage (6g Tang-min-ling pills every time), placebo by 3
      times every day for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycosylated hemoglobin</measure>
    <time_frame>0 and 12weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose,2-hour postprandial blood glucose,true insulin,TG,TG、LCL-C、HDL-C、BMI,waistline, hipline,TCM syndrome and sign</measure>
    <time_frame>baseline and 12 week after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>controlled group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tang-min Lin analogue 6g,tid,po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tang-min Lin pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tang-min Lin pills 6g,tid,po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tang-min Lin pill</intervention_name>
    <description>Tang-min Lin pill 6g,tid,treat 12 weeks.</description>
    <arm_group_label>controlled group</arm_group_label>
    <arm_group_label>Tang-min Lin pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  initial treatment type 2 diabetic patient

          -  liver-stomach heat retention syndrome

          -  BMI ≥24kg/m2

          -  aged 30-65 years

          -  after screening stage(lifestyle intervention),Hba1C≥7.0%,FPG7.0-13.3mmol/L or
             PG2h＞11.1mmol/L;

          -  voluntary signs the informed consent

        Exclusion Criteria:

          -  have used anti-diabetes drug before more than 1 month

          -  used drug to control the blood sugar with 3 weeks

          -  diabetic ketosis,keto-acidosis,serious infection or trauma,major surgery within 1
             month

          -  liver or kidney insufficiency,lung insufficiency,heart failure,acute myocardial
             infarction or other serious primary disease

          -  SBP/DBP ＞160mmHg/100 mmHg

          -  serious chronic diabetic complication

          -  chronic stomach-intestine disease,bad condition of the whole body

          -  pregnancy,preparing to pregnant,or breast-feed stage women

          -  allergic to TCM component

          -  mental disease

          -  allergic habitus

          -  attending to other clinical test

          -  attended this test before

          -  bibulosity and/or mental active drug,drug abuse or depend

          -  usually change the working environment,unstable live environment,etc.which will
             complied the inclusion

          -  unstable dose or type of anti-hypertension drug

          -  taking the drug or health food which will change the body weight
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu S Tao, pro.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tian Jin university of tradtional chinese medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lian F Mei, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TCM school of Jiang Su province</name>
      <address>
        <city>Nan Jing</city>
        <state>Jiang Su</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoning University of Traditional Chinese Medicine</name>
      <address>
        <city>Shen Yang</city>
        <state>Liao Ning</state>
        <zip>116600</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shang Hai</city>
        <state>Shang Hai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tian Jin traditional chinese medicine university</name>
      <address>
        <city>Tian Jin</city>
        <state>Tian Jin</state>
        <zip>300193</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>March 15, 2010</last_update_submitted>
  <last_update_submitted_qc>March 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Department of drug clinical trail institution</name_title>
    <organization>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</organization>
  </responsible_party>
  <keyword>Tang-min Lin pills</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>liver and stomach heat retention</keyword>
  <keyword>Evaluate the safety and efficacy of Tang-min Lin pills</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

